BioXcel Therapeutics Inc expected to post a loss of $6.66 a share - Earnings Preview

BioXcel Therapeutics

05/05/2025 13:57

BioXcel Therapeutics Inc BTAI.OQ BTAI.O is expected to show a fall in quarterly revenue when it reports  results on May 7 (estimated) for the period ending March 31 2025

The New Haven Connecticut-based  company is expected to report a 26.7% decrease in revenue to $426.67 thousand from $582 thousand a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

​LSEG's mean analyst estimate for BioXcel Therapeutics Inc is for a loss of $6.66 per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 3 "hold" and 1 "sell" or "strong sell."

The mean earnings estimate of analysts had risen by about 2.5% in the last three months. ​

Wall Street's median 12-month price target for BioXcel Therapeutics Inc is $16.00​, above​ its last closing price of $1.78. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-6.04
-6.42
-3.57
Beat
44.4
Sep. 30 2024
-8.00
-8.67
-5.12
Beat
40.9
Jun. 30 2024
-11.12
-11.36
-3.36
Beat
70.4​
Mar. 31 2024
-10.25
-11.17
-13.92
Missed
-24.6
​​Dec. 31 2023
-15.12
-14.56
-12.16
Beat
16.5
Sep. 30 2023
-21.50
-20.86
-27.52
Missed
-31.9​
Jun. 30 2023
-28.83
-28.01
-29.28
Missed
-4.5
Mar. 31 2023
-28.96
-25.89
-29.44
Missed
-13.7

This summary was machine generated May 5 at 12:57 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)